Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans

Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation

Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings

FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder